)
Overview
<ul>
<li>Biotechnology firm reported Q4 EPS and net income beat analyst expectations</li>
<li>Company entered strategic financing agreement with Sixth Street for up to $500 mln</li>
<li>Company expanded liver-targeted genetic disease franchise with BEAM-304 for PKU</li>
</ul>
Outlook
<ul>
<li>Beam expects to file IND for BEAM-304 in 2026</li>
<li>Beam plans BLA submission for risto-cel by year-end 2026</li>
<li>Beam anticipates updated BEAM-302 data by Q1 2026</li>
</ul>
Result Drivers
<ul>
<li>BEAM-304 EXPANSION - Beam expanded its liver-targeted genetic disease franchise with BEAM-304 for PKU, leveraging base editing technology to address mutations in the PAH gene</li>
<li>STRATEGIC FINANCING - Beam secured a strategic financing agreement with Sixth Street for up to $500 mln to support the launch of risto-cel in SCD Company press release:</li>
</ul>
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
<h3>Q4 $114.11</h3>
License mln
and
Collabor
ation
Revenue
Q4 EPS Beat $2.33 -$0.99
(15
Analysts
)
Q4 Net Beat $244.30 -$91.17
Income mln mln (15
Analysts
)
Q4 Beat -$17.45 -$117.30
Operatin mln mln (14
g Income Analysts
)
Q4 Beat $244.30 -$95.99
Pretax mln mln (13
Profit Analysts
)
<h3>Q4 $131.55</h3>
Operatin mln
g
Expenses
Analyst Coverage
<ul>
<li>The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 17 “strong buy” or “buy”, 2 “hold” and no “sell” or “strong sell”</li>
<li>The average consensus recommendation for the biotechnology &amp; medical research peer group is “buy”</li>
<li>Wall Street’s median 12-month price target for Beam Therapeutics Inc is $45.00, about 58.8% above its February 23 closing price of $28.33 For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</li>
</ul>

IBBQ

SBIO

BEAM

Reuters

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Beam Therapeutics

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Beam Therapeutics tops Q4 profit estimates, signs financing deal